European Commission logo
English English
CORDIS - EU research results
CORDIS

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Project description

New immunotherapy targets cancerous cells that are immune to current treatment

Liver fibrosis is a scarring process resulting from the liver's response to chronic injury or inflammation. It is caused by viruses, diseases, and alcoholism. Over time, it can lead to cirrhosis, a disruption in the organisation of the functional units of the liver that can eventually impede blood flow to the liver. Fibrosis and cirrhosis are also linked to the development of an aggressive and lethal form of liver cancer. The cancer is characterised by emergence of drug-resistant cell populations in response to the only systemic treatment currently available. Even worse, persistent treatment seems to speed tumour progression. HEPCAN is targeting those drug-resistant cell populations through the development of powerful monoclonal antibodies designed to decimate the resistors.

Objective

Hepatocellular carcinoma is the most frequent primary liver cancer and owing to its very aggressive nature is amongst the leading cause of cancer mortality worldwide (IARC). The number of liver cancer-related deaths in Europe in 2018 amounted to 77 375, and this number is expected to keep rising, reaching an estimated number of more than 100 000 deaths in 2040 (IARC). Major causes include the hepatitis B and C viruses, alcoholism, Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. All of these medical conditions trigger liver fibrosis by damaging the liver and are closely associated with the development of HCC. As a matter of fact, more than 80% of HCC develop in fibrotic or cirrhotic livers. Early stages of liver cancer do not usually produce symptoms, and many challenges are associated with the screening of HCC, leading to its late diagnosis. The absence of effective drug treatment for HCC makes its resection the first curative option with most of the patients experiencing HCC recurrence within 5 years. All these factors contribute to the poor prognosis of the HCC patients. Sorafenib is the only currently approved systemic therapy for advanced HCC in the EU, only prolonging survival by an average of 3 months, the treatment often leads to drug resistance. Indeed, intra-tumor heterogeneity strongly constrains the therapeutic benefit of precision medicine and triggers drug-resistant sub-population of cells. Consequently, persistent treatment of drug-resistant tumor cells may accelerate tumor progression, suggesting that inappropriate and continual use of a compound on drug-resistant cancer cells is not recommended. Thus, there is an urgent unmet medical need to identify and to validate the therapeutic efficacy of new valuable molecules – i.e. targeting the existing drug-resistant cell populations -that could be used in monotherapy or in combination therapy with FDA-approved drugs to improve HCC treatment responses.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 150 000,00
Address
RUE DE TOLBIAC 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)